We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $214M
1-Year Est. Return 185.33%
This Fund
S&P 500
This Quarter Est. Return
-17.39%
1 Year Est. Return
+185.33%
3 Year Est. Return
+327.48%
5 Year Est. Return
+458.62%
10 Year Est. Return
+1,549.55%
AUM
$155M
AUM Growth
-$33.9M
Cap. Flow
+$9.51M
Cap. Flow %
6.12%
Top 10 Hldgs %
89.26%
Holding
44
New
3
Increased
6
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$7.92M
2
SIEN
Sientra, Inc.
SIEN
+$1.55M
3
QTNT
Quotient Limited Ordinary Shares
QTNT
+$625K
4
NBIX icon
Neurocrine Biosciences
NBIX
+$469K
5
OVV icon
Ovintiv
OVV
+$391K

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$650K
2
MDVN
MEDIVATION, INC.
MDVN
+$525K
3
COLL icon
Collegium Pharmaceutical
COLL
+$362K
4
NSPR icon
InspireMD
NSPR
+$188K
5
CALA
Calithera Biosciences, Inc
CALA
+$141K

Sector Composition

Rank Sector Weight
1 Healthcare 90.48%
2 Energy 4.24%
3 Miscellaneous 3.29%
4 Consumer Staples 1.81%
5 Technology 0.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$86.1M 55.44%
796,351
+63,798
+9% +$7.92M
AXDX
2
DELISTED
Accelerate Diagnostics
AXDX
$33.5M 21.53%
206,756
– –
VRML
3
DELISTED
Vermillion, Inc.
VRML
$5.43M 3.5%
2,717,514
– –
YTEN
4
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$2.81M 1.81%
236
– –
EQT icon
5
EQT Corp
EQT
$34.4B
$2.74M 1.76%
77,705
+1,837
+2% +$74.9K
CFRX
6
DELISTED
ContraFect Corporation
CFRX
$2.02M 1.3%
569
– –
HNSN
7
DELISTED
HANSEN MEDICAL, INC. COM NEW
HNSN
$1.99M 1.28%
528,144
– –
MASI
8
DELISTED
Masimo
MASI
$1.41M 0.91%
36,600
– –
MDVN
9
DELISTED
MEDIVATION, INC.
MDVN
$1.39M 0.9%
32,760
-10,600
-24% -$525K
COLL icon
10
Collegium Pharmaceutical
COLL
$786M
$1.3M 0.84%
58,768
-20,000
-25% -$362K
GILD icon
11
Gilead Sciences
GILD
$187B
$1.26M 0.81%
12,820
-5,850
-31% -$650K
SWN
12
DELISTED
Southwestern Energy Company
SWN
$1.22M 0.79%
96,483
– –
BIOL
13
DELISTED
Biolase, Inc.
BIOL
$1.07M 0.69%
95
– –
OMED
14
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$974K 0.63%
58,689
– –
CLR
15
DELISTED
CONTINENTAL RESOURCES INC.
CLR
$947K 0.61%
32,674
– –
OVV icon
16
Ovintiv
OVV
$18B
$852K 0.55%
26,460
+10,200
+63% +$391K
QTNT
17
DELISTED
Quotient Limited Ordinary Shares
QTNT
$757K 0.49%
1,455
+1,000
+220% +$625K
MRK icon
18
Merck
MRK
$372B
$741K 0.48%
15,720
– –
QDEL icon
19
QuidelOrtho
QDEL
$960M
$736K 0.47%
38,975
– –
SIEN
20
DELISTED
Sientra, Inc.
SIEN
$693K 0.45%
+6,830
New +$1.55M
AEGR
21
DELISTED
Aegerion Pharmaceuticals
AEGR
$626K 0.4%
46,000
– –
TRNX
22
DELISTED
TORNIER N V SHARES (NLD)
TRNX
$612K 0.39%
30,000
– –
ARAY icon
23
Accuray
ARAY
$31.3M
$601K 0.39%
120,300
– –
CTRA
24
DELISTED
Coterra Energy
CTRA
$459K 0.3%
21,000
– –
PTCT icon
25
PTC Therapeutics
PTCT
$5.83B
$451K 0.29%
16,900
– –
1
2

Similar funds

EFIC
Eliot Finkel Investment Counsel Beverly Hills, California $214M AUM 62.72% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return
TCM
Tassel Capital Management Matthews, North Carolina $214M AUM 16.99% 1-Year Est. Return
EFS
Econ Financial Services Harrisburg, Pennsylvania $214M AUM 10.53% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $214M AUM 47.29% 1-Year Est. Return
KWM
Kingsman Wealth Management Pensacola, Florida $214M AUM 46.9% 1-Year Est. Return
FA
Fortis Advisors Wayne, Pennsylvania $214M AUM 41.3% 1-Year Est. Return
MSWM
Mader & Shannon Wealth Management Kansas City, Missouri $214M AUM 23.75% 1-Year Est. Return

Birchview Capital's Q3 2015 Portfolio in Review

As of Q3 2015, Birchview Capital held 44 positions worth $155M, down 18% from $189M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Birchview Capital deployed $9.51M of net new capital in Q3 2015, opening 3 new positions and adding to 6 existing holdings. Its largest new stake was Sientra, Inc.: 6,830 shares worth $693K.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 86% a quarter earlier, followed by Energy and Miscellaneous.

On the sell side, the largest reduction was Gilead Sciences, an estimated $650K trimmed.

  • Birchview Capital's largest Q3 2015 buy was Sientra, Inc.: 6,830 shares worth $693K.
  • Birchview Capital added most to Celgene Corp in Q3 2015, an estimated $7.92M increase.
  • Birchview Capital's biggest Q3 2015 reduction was Gilead Sciences, cutting an estimated $650K.
  • Birchview Capital fully exited Calithera Biosciences, Inc in Q3 2015, selling an estimated $141K.
  • Birchview Capital's ten largest holdings make up 89% of its $155M portfolio in Q3 2015.
  • Birchview Capital opened 3 new positions and closed 1 in Q3 2015.
  • Birchview Capital's portfolio value fell 18% quarter-over-quarter to $155M.

Based on Birchview Capital's 13F filing for Q3 2015, filed 6 Nov 2015.